Viridian Therapeutics, Inc.\DE (VRDN) Current Deferred Revenue (2020 - 2025)
Historic Current Deferred Revenue for Viridian Therapeutics, Inc.\DE (VRDN) over the last 6 years, with Q2 2025 value amounting to $288000.0.
- Viridian Therapeutics, Inc.\DE's Current Deferred Revenue changed 0.0% to $288000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $288000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $288000.0 for FY2024, which is 0.0% changed from last year.
- Per Viridian Therapeutics, Inc.\DE's latest filing, its Current Deferred Revenue stood at $288000.0 for Q2 2025, which was down 0.0% from $288000.0 recorded in Q1 2025.
- Viridian Therapeutics, Inc.\DE's 5-year Current Deferred Revenue high stood at $289000.0 for Q4 2021, and its period low was $288000.0 during Q1 2021.
- Moreover, its 5-year median value for Current Deferred Revenue was $288000.0 (2021), whereas its average is $288055.6.
- As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Current Deferred Revenue tumbled by 398.67% in 2021, and later changed by 0.0% in 2022.
- Over the past 5 years, Viridian Therapeutics, Inc.\DE's Current Deferred Revenue (Quarter) stood at $289000.0 in 2021, then fell by 0.35% to $288000.0 in 2022, then changed by 0.0% to $288000.0 in 2023, then changed by 0.0% to $288000.0 in 2024, then changed by 0.0% to $288000.0 in 2025.
- Its Current Deferred Revenue stands at $288000.0 for Q2 2025, versus $288000.0 for Q1 2025 and $288000.0 for Q4 2024.